Barry Gruber, MD
Rheumatology · Babylon, NYNPI 1710912431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $602,605 of the $742,177 with a category attached, or 81.2%. Amgen accounts for 63.0% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2019 at $245,006 and has fallen 54.2% since, to $112,194 in 2025. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,924 payments — averaging $385.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$467K
- Boehringer Ingelheim$42K
- Radius Health, Inc.$42K
- Pacira Therapeutics, Inc.$32K
- AbbVie$29K
- United Rheumatology$29K
- plus $101K from 45 others
Across 42 payments — averaging $4297.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$146K
- Radius Health, Inc.$34K
What the payments were for
- Consulting fees$66,0949%
- Speaking & faculty fees$602,60581%
- Travel & lodging$27,1524%
- Food & beverage$45,3856%
- Education$9420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$742,177 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 424 | $694,896 |
| RinvoqUpadacitinib | 66 | $452,624 |
| Humira(Cf) PenAdalimumab | 33 | $280,788 |
| ActemraTocilizumab | 45 | $176,828 |
| Xeljanz XrTofacitinib Citrate | 14 | $83,057 |
| EnbrelEtanercept | 11 | $76,316 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 31 | $72,927 |
| OrenciaAbatacept/Maltose | 17 | $66,043 |
| Teriparatide | 20 | $59,838 |
| SaphneloAnifrolumab-Fnia | 11 | $55,364 |
| RemicadeInfliximab | 12 | $52,692 |
| RidauraAuranofin | 12 | $18,896 |
| Hydroxychloroquine Sulfate | 70 | $2,828 |
| Duloxetine Hcl | 115 | $2,079 |
| Celecoxib | 65 | $2,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Enbrel, Evenity (2 Syringes) | $467,376 | $844,139466 claims |
| AbbVieRinvoq | $29,021 | $452,62466 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $26,501 | $66,04317 claims |
| Alvogen IncTeriparatide | $25 | $59,83820 claims |
| AstraZenecaSaphnelo | $483 | $55,36411 claims |
| Johnson & JohnsonRemicade | $5,023 | $52,69212 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $19 | $1,66612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 541 rheumatology providers in New York.
Other rheumatology in Babylon
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Olga PetrynaNew York$509K
- Sanjay GodhwaniWading River$472K
- Danielle PeterselNew York$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.